Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can ancient and modern medicine team up to predict colon cancer risk?

NCT ID NCT07611266

Knowledge-focused Sponsor: Beijing Friendship Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is building a risk prediction model for colorectal adenomas (precancerous polyps) by combining data from both Traditional Chinese Medicine (like tongue and pulse diagnosis) and Western medicine (like endoscopy and lab tests). Researchers will follow 3,000 adults across multiple hospitals in China to see which factors best predict polyp recurrence or cancer. The goal is to create a tool that helps doctors identify high-risk patients and tailor prevention strategies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a tool that helps doctors predict which patients are at higher risk of colorectal adenoma recurrence or cancer, enabling earlier and more personalized prevention.
What could go wrong
This is an observational study, not a treatment trial. The model may not be accurate enough for widespread use, and results may take years to validate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 3,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Prospective inclusion of patients with pathologically diagnosed colorectal adenomas from 2025 in Beijing Friendship Hospital Affiliated to Capital Medical University, Guang'anmen Hospital of the Chinese Academy of Traditional Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Cancer Hospital of the Chinese Academy of Medical Sciences, and Beihang University

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Meet the diagnostic criteria for colorectal adenoma (Western medicine) and the relevant TCM syndromes. * Aged 18 years or older. * Willing to undergo regular follow-up examinations (including colonoscopy and laboratory tests) and sign the informed consent form. Exclusion Criteria: * Pregnant or lactating women. * History of Crohn's disease, ulcerative colitis, or other malignancies. * Previous history of radiotherapy, chemotherapy, or gastrointestinal surgery. * Hereditary polyposis syndromes (e.g., familial adenomatous polyposis, MUTYH-associated polyposis, or hamartomatous polyposis syndrome). * Severe cognitive impairment, dementia, or mental illness. * Severe cardiovascular or cerebrovascular diseases, or hematological system disorders.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal adenoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal adenoma colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer control and prevention

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Friendship Hospital Affiliated to Capital Medical University

    RECRUITING

    Beijing, Beijing Municipality, 100000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.